Generic Medicine Info
Porphyria. Comatose states, CNS depression, phaeochromocytoma, lactation, history of blood disorders.
Special Precautions
Hepatic impairment, renal impairment, CV disease, Parkinson's disease, epilepsy, depression, myasthenia gravis, prostatic hypertrophy, severe respiratory disease, blood dyscrasias, history of jaundice. Elderly. May affect driving, especially during the initial part of the treatment. Pregnancy.
Adverse Reactions
Extrapyramidal effects in neonates have been reported. Parkinsonian symptoms, dystonia, akathisia, tardive dyskinesia. Interference with temperature regulation. Neuroleptic malignant syndrome. CNS effects, GI disturbances, nasal congestion, antimuscarinic symptoms, CV effects, ECG changes, endocrine effects, blood dyscrasias, photosensitisation, contact sensitisation and rashes, hepatitis and jaundice, corneal and lens opacities and purplish pigmentation of the skin, cornea, conjunctiva and retina.
Potentially Fatal: Aplastic anaemia.
Drug Interactions
Serum levels may be decreased by concurrent use with antacids containing aluminium/magnesium hydroxide and sucralfate. Increased risk of adverse effects when used with moclobemide.
Description: Remoxipride is an atypical antipsychotic that has high selectivity for dopamine D2-receptors. It had been used for the treatment of schizophrenia and other psychoses, but was withdrawn due to reports of aplastic anaemia; though still remain available for the treatment of refractory psychoses.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Remoxipride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in